The chronic effects of hydrogen-rich water on people with Parkinson's disease

Not Applicable

• Conditions: Parkinson's disease; Nervous System Diseases

• Registration Number: ISRCTN17961308
• Lead Sponsor: niversity of Kent

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-05-10
• Last Update Posted: 4 December 2023
• Study Completion: 2024-03-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. All participants must have a diagnosis of PD by a Neurologist or Geriatrician
2. All participants must be at stage 2 or stage 3 on the Hoehn and Yahr (H&Y) scale. Stage 1 is too mild and stages 4 and 5 could potentially be too severe for appropriate study participation
3. Male or female
4. Able to consume 1 l of HRW or PLA per day
5. All participants' disease should be in a stable state for the past 2 months

Exclusion Criteria

1. Participants whose Parkinson’s is not controlled.
2. Participants who are at stage 1, stage 4 and stage 5 of the H&Y scale.
3. Participants who cannot consent for themselves.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cognitive function and manual dexterity to be measured using a Purdue Pegboard Test (the three-trial administration test-retest will be used to increase reliability) at baseline, after 1 week, after 4 weeks of HRW and PLA consumption.

Secondary Outcome Measures

Name	Time	Method
<br> Measures 1-4 will be assessed at time points of: baseline, week 1, week 4, week 5, week 6, week 9:<br> 1.Transient mood measured using a Profile of Mood States (POMS)– Short Form.<br> 2. Visual attention measured using The Flanker Compatibility Task<br> 3. The burden of non-motor symptoms, including non-motor fluctuations, using the Movement Disorder Society Non-Motor Rating Scale<br> 4. Blood markers of oxidative stress, inflammation/neuro inflammation and BDNF will measured in serum or plasma derived from venous blood samples.<br> 5. Physical activity levels will be measured using an activity tracker worn for a total of eight weeks.<br>